肿瘤细胞治疗研究
英文原题：Natural Killer Cell-Based Immunotherapy against Glioblastoma.
尽管采用了包括手术切除、放射治疗、化疗和肿瘤电场治疗在内的多模式治疗，诊断后的中位总生存期（OS）仍约为 2 年，5 年 OS 较差。
胶质母细胞瘤（GBM）是成人最具侵袭性和恶性程度最高的原发性脑肿瘤。尽管采用手术切除、放疗、化疗和肿瘤电场治疗等多模式治疗，确诊后中位总生存期约为2年，5年总生存率仍较低。鉴于预后不良，需要开发新治疗策略，例如免疫疗法，包括CAR-T 细胞疗法、免疫检查点抑制剂、疫苗疗法和溶瘤病毒疗法。然而这些疗法尚未获得满意结局，原因之一是它们主要依靠活化T细胞来控制GBM进展。基于自然杀伤（NK）细胞的免疫疗法具有新特点，可通过不同于T细胞免疫疗法的机制识别GBM。本综述聚焦基于NK细胞免疫疗法这一新型GBM治疗策略。
Glioblastoma (GBM) is the most aggressive and malignant primary brain tumor in adults. Despite multimodality treatment involving surgical resection, radiation therapy, chemotherapy, and tumor-treating fields, the median overall survival (OS) after diagnosis is approximately 2 years and the 5-year OS is poor. Considering the poor prognosis, novel treatment strategies are needed, such as immunotherapies, which include chimeric antigen receptor T-cell therapy, immune checkpoint inhibitors, vaccine therapy, and oncolytic virus therapy. However, these therapies have not achieved satisfactory outcomes. One reason for this is that these therapies are mainly based on activating T cells and controlling GBM progression. Natural killer (NK) cell-based immunotherapy involves the new feature of recognizing GBM via differing mechanisms from that of T cell-based immunotherapy. In this review, we focused on NK cell-based immunotherapy as a novel GBM treatment strategy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
